LIT-001

LIT-001

L646912-5mg

5mg

≥98%

2-8°C储存,干燥

冰袋运输

LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist ( EC 50 =55 nM; K i =226 nM). LIT-001 improves social interaction in a mouse model of autism In Vitro In vitro signaling experiments, LIT-001 is a nonbiased OT-R agonist on the two main signaling pathways of this receptor, with minor antagonist effect on V1a and agonist effect on V1b receptors, observed at high concentrations only. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD ) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Oprm1 –/– mice (bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background) Dosage: 10, 20 mg/kg Administration: i.p. Result: Alleviated core symptoms in the context of ASD. Form:Solid IC50& Target:EC50: 55 nM (OT-R), Ki: 226 nM (OT-R)

LIT-001 是首个非肽催产素受体（OT-R）激动剂（EC 50 =55 nM；K i =226 nM）。LIT-001 可改善自闭症小鼠模型的社会互动。

2245072-21-1

C30H34F3N7O4S

645.7 g/mol

145711713

(2S)-2-(dimethylcarbamothioyl)-N-[[2-methyl-4-(1-methyl-4,10-dihydropyrazolo[4,3-c][1,5]benzodiazepine-5-carbonyl)phenyl]methyl]pyrrolidine-1-carboxamide;2,2,2-trifluoroacetic acid

1S/C28H33N7O2S.C2HF3O2/c1-18-14-19(11-12-20(18)15-29-28(37)34-13-7-10-24(34)27(38)32(2)3)26(36)35-17-21-16-30-33(4)25(21)31-22-8-5-6-9-23(22)35;3-2(4,5)1(6)7/h5-6,8-9,11-12,14,16,24,31H,7,10,13,15,17H2,1-4H3,(H,29,37);(H,6,7)/t24-;/m0./s1

BZHSRXWFCSEPQQ-JIDHJSLPSA-N

CC1=C(C=CC(=C1)C(=O)N2CC3=C(NC4=CC=CC=C42)N(N=C3)C)CNC(=O)N5CCCC5C(=S)N(C)C.C(=O)(C(F)(F)F)O

145711713

(S)-2-(Dimethylcarbamothioyl)-N-(2-methyl-4-(1-methyl-1,4,5,10-tetrahydrobenzo(b)pyrazolo(3,4-e)(1,4)diazepine-5-carbonyl)benzyl)pyrrolidine-1-carboxamide 2,2,2-trifluoroacetate;LIT-001

DMSO : 100 mg/mL (154.87 mM; Need ultrasonic)